Patient Access Channel PTC's RareMed Solutions launched non commercial pharmacy dispensing services for Sephience, creating a scalable patient access channel that can be extended to additional therapies and partnered with payers and specialty pharmacies.

Pipeline Licensing PTC-518 is in Phase 2, and with current revenue and a substantial funding runway the company is well positioned to pursue licensing or co development deals with large pharma or specialty partners to accelerate development and commercialization.

Financial Capacity Strong revenue base and $1B in funding provide capital to support collaborations, manufacturing scale up, and potential international expansion, reducing barriers to BD deals and enabling favorable deal structures.

Strategic Leadership New board member Jessica Chutter and active investor relations activities, including presenting at the J.P. Morgan Healthcare Conference, signal readiness for strategic partnerships and executive level BD engagement.

Patient Focus Advantage Gallup Exceptional Workplace Award and a patient centered mission bolster collaboration with patient advocacy groups, accelerate clinical trial recruitment, and support payer access programs, strengthening PTC's position in rare diseases.